Develop and manufacture biotherapeutics that address significant medical needs.
H.R. 3200, America's Affordable Health Choices Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics.
Senate Finance Committee Chairman's Mark, America's Healthy Future Act - Medicare and Medicaid reimbursement for biotherapeutics. H.R. 3200, America's Affordable Health Choices Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics.
S. 1679, the Affordable Health Choices Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics. Senate Finance Committee Chairman's Mark, America's Healthy Future Act - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research. H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics.
H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics.
H.R. 3200, America's Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period.
S. 1679, the Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program.
Senate Finance Committee Chairman's Mark, America's Healthy Future Act - Medicare and Medicaid reimbursement issues, possible taxes and fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit.
S. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs. Public Law 111-5, the American Recovery and Reinvestment Act of 2009 - funding for comparative effectiveness research.
S. 1213, the Patient-Centered Outcomes Research Act of 2009 - authorization for comparative effectiveness research.
H.R. 3200, America's Affordable Health Choices Act of 2009 - authorization for comparative effectiveness research.
Senate Finance Committee Chairman's Mark, America's Healthy Future Act - authorization for comparative effectiveness research.
MMM - Medicare/Medicaid HCR - Health Issues PHA - Pharmacy MED - Medical/Disease Research/Clinical Labs
11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
TARPLIN STRATEGIES LLC
975 F Street NW Suite 500, Washington, DC, 20004, US
RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families) RICHARD JOSEPH TARPLIN (and Families)
and Families and Families and Families and Families